Skip to main content
Fig. 2 | Trials

Fig. 2

From: The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

Fig. 2

APEX study schema. The APEX trial includes a 6-week screening period, 24-week placebo-controlled period, 24-week active treatment period, open-label long-term extension period from W48 through W156, and safety follow-up through W60 (final safety visit for patients who do not enter LTE) or W168 (final safety visit for patients who enter LTE). EE if <20% improvement from baseline in tender and swollen joint counts at W16, patients may initiate or increase dose of one permitted concomitant medication up to the maximum allowed dose

Back to article page

Trials

ISSN: 1745-6215